Dabrafenib and trametinib are highly efficacious therapies in patients with <i>BRAF</i> V600E-mutated lung adenocarcinoma (LUAD), but they are occasionally associated with the development of hemophagocytic lymphohistiocytosis (HLH). This evidence concerns the gene BRAF and hemophagocytic syndrome.